Shanghai Junshi Biosciences
Shanghai Junshi Biosciences Co Ltd is a Chinese biopharmaceutical enterprise focused on discovering, developing, and commercializing novel immunotherapies and monoclonal antibodies. The company commercializes Tuoyi (toripalimab), a anti-PD-1 monoclonal antibody for melanoma, nasopharyngeal carcinoma, and lung cancer, alongside developing antibody therapeutics for autoimmune and metabolic diseases. Main revenue drivers comprise commercial sales of Tuoyi, development milestone achievements, and out-licensing royalties from global partners like Coherus BioSciences. Shanghai Junshi Biosciences targets medical oncologists, hospital networks, prescription pharmacies, and cancer patients in China, North America, and Europe. The company holds an innovative market position as a developer of China's first domestically produced anti-PD-1 monoclonal antibody. Headquartered in Shanghai, China, it is listed on the Shanghai Stock Exchange and Hong Kong Stock Exchange.
3 of the funds FundTelligence covers report a position in Shanghai Junshi Biosciences.
- Legal name
- Shanghai Junshi Biosciences Co Ltd
- Sector
- Health Care
- Country
- China
- Funds holding it
- 3
Funds holding Shanghai Junshi Biosciences
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.04 % (full portfolio disclosed, October 2026)
- Handelsbanken Emerging Markets Index — Handelsbanken · 0.03 % (full portfolio disclosed, September 2026)
- Handelsbanken Global Index Criteria — Handelsbanken · 0.01 % (full portfolio disclosed, September 2026)